SEC Form 4 · accession 0001209191-16-152814
Aimmune Therapeutics, Inc. · AIMT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Patrick G Enright
Director · 10% Owner
Period of report
Nov 29, 2016
Accepted (ET)
Dec 1, 2016 · 9:52 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001631650
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock, $0.0001 par valueF2 | Nov 29, 2016 | J | 1,500,000 | $0.00 | D | 6,013,134 | I | By Longitude Venture Partners II, L.P. |
| Common Stock, $0.0001 par value | Nov 29, 2016 | J | 7,276 | $0.00 | A | 7,276 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Represents a pro rata distribution of shares of common stock of the Issuer held of record by Longitude Venture Partners II, L.P. ("Longitude Venture II") to its partners for no consideration. Longitude Capital Partners II, LLC ("Longitude Capital II"), the sole general partner of Longitude Venture II, received a pro rata allocation of the distributed shares in accordance with its ownership, and further distributed its allocation to its managing members.
- F2Reflects transactions and holdings of shares of common stock of the Issuer held of record by Longitude Venture II. Patrick G. Enright is a managing member of Longitude Capital II. Mr. Enright serves on the Board of Directors of the Issuer as the nominee of Longitude Venture II. Mr. Enright disclaims beneficial ownership of the securities of the Issuer held of record by Longitude Venture II, except to the extent of his pecuniary interest therein.